Skip to content
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
IFPMA
  • Who We Are
    • IFPMA in Brief
    • Our Governance and Leadership
    • Our Membership
      • Full Members
        • Associations
        • Companies
      • Affiliate Members
    • Our Experts
    • Join Us
  • Topics
  • News Center
    • News Releases
    • Blog
      • Global Health Matters
      • Science Matters
      • Contributors
    • Statements
    • Latest News from Our Members
  • Resources
    • Publications
      • News Releases
      • Statements
      • Position Papers
      • Publications
      • External Studies
      • Infographics
      • Event Highlights
    • Multimedia
      • Interviews
      • Podcasts
      • Videos
      • Photos
      • Slides
    • IFPMA Interactive Platforms
      • Global Health Progress
      • 50 Years of Global Health Progress
  • Events
    • Upcoming IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
    • Past IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
  • Partners
  • BCR
  • Discovering medicines and Vaccines
  • Strengthening Regulatory Systems
  • Building trust
  • Boosting Innovation and Access
  • Tackling Global health challenges
Economic footprint IP Pharma by numbers Sustainable innovation Value of innovation

spotlight

Value of innovation

Discovering medicines and Vaccines
Biosimilars Biotherapeutic medicines Falsified medicines Import testing Pharma by numbers Pharmacovigiliance Quality, safety, and efficacy Regulatory conferences Regulatory system strengthening / Harmonization Supply chain The Africa Regulatory Network (ARN) The ARN: Le réseau africain de réglementation pharmaceutique

spotlight

Pharmacovigiliance

Strengthening Regulatory Systems
New IFPMA Code of Practice (2019) IFPMA Code of Practice 2019 - Our Ethos Code training Code of practice operating procedure Code of practice: how to file a complaint? Complaint submission form Cases Consensus framework for ethical collaboration

spotlight

New IFPMA Code of Practice (2019)

Building trust
Access to medicines Health technology assessment IP Pharma by numbers Trade

spotlight

Access to medicines

Boosting Innovation and Access
Ageing Antimicrobial resistance Cancer Child and maternal health Diabetes Do you mind? campaign Ebola Falsified medicines Health partnerships HIV/AIDS Humanitarian and disaster relief aid Influenza vaccine Malaria Mental and neurological disorders Neglected tropical diseases Non-communicable diseases Pandemic influenza preparedness Pharma by numbers Psoriasis Rare diseases Seasonal influenza Supply chain Sustainable development goals Tuberculosis Universal Health Coverage Vaccines innovation Vaccines protect communities Vaccines sustainability Value of immunization Viral hepatitis Workplace wellness Zika Virus

spotlight

Universal Health Coverage

Tackling Global health challenges

  • Home
  • >
  • Resources
  • >
  • Infographics
  • >
  • Doing our part: landmark medicine donations

Doing our part: landmark medicine donations

Published on: 17 February 2015

IFPMA_Small_Infographic_NTDs_Donations_Feb_2015_FINAL

Downloads

» Infographic

Resources

Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions
Publications

Publications


Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions

Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations
Publications

Publications


Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations

New report shows major increase in pharmaceutical research and development (R&D) for neglected diseases
News Releases

News Releases


New report shows major increase in pharmaceutical research and development (R&D) for neglected diseases

Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations
Publications

Publications


Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations

WHA 66, Item 16.2, Neglected tropical diseases
Statements

Statements


WHA 66, Item 16.2, Neglected tropical diseases

Open letter to G7 Heads of State on neglected tropical diseases
News Releases

News Releases


Open letter to G7 Heads of State on neglected tropical diseases


Related Topics

Neglected tropical diseases

Tags

  • Capacity
  • Donations
  • IFPMA
  • Infographics
  • Medicines
  • Neglected Tropical Diseases
  • NTDs
  • Partnerships
  • PDPs
  • Pharma
  • Pharmaceuticals
  • R&D
  • Research
  • Vaccines
IFPMA

Chemin des Mines 9
P.O. BOX 195
1211 Geneva 20
Switzerland

+41 22 338 32 00
info@ifpma.org

  • Careers
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Access to Our Extranet
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
Designed and Produced by ACW ^ Back to Top
Cookie Policy
This website uses cookies to ensure you get the best experience on our website. Learn More
Decline Allow Cookies